Label: ALHEMO- concizumab injection, solution

  • NDC Code(s): 0169-2080-15, 0169-2081-03, 0169-2084-15
  • Packager: Novo Nordisk
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Biologic Licensing Application

Drug Label Information

Updated December 2, 2024

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use Alhemo safely and effectively. See full prescribing information for Alhemo. Alhemo® (concizumab-mtci) injection, for subcutaneous ...
  • Table of Contents
    Table of Contents
  • 1 INDICATIONS AND USAGE
    Alhemo is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: • hemophilia A (congenital ...
  • 2 DOSAGE AND ADMINISTRATION
    2.1 Recommended Dosage - For subcutaneous use only. Alhemo should be administered once-daily. Avoid missed doses. Recommended dosing regimen: • Day 1: Loading dose of 1 mg/kg - • Day 2 ...
  • 3 DOSAGE FORMS AND STRENGTHS
    Alhemo injection is a clear to slightly opalescent and colorless to slightly yellow solution that may contain translucent to white particles, available in the following presentations: • 60 mg/1.5 ...
  • 4 CONTRAINDICATIONS
    Alhemo is contraindicated in patients with a history of known serious hypersensitivity to Alhemo or its components or the inactive ingredients [see Warnings and Precautions (5.1) and Description ...
  • 5 WARNINGS AND PRECAUTIONS
    5.1 Thromboembolic Events - Venous and arterial thromboembolic events were reported in 1.3% of patients (4/320) in Alhemo clinical trials. These cases occurred in patients with multiple risk ...
  • 6 ADVERSE REACTIONS
    The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: • Thromboembolic Events [see Warnings and Precautions ...
  • 7 DRUG INTERACTIONS
    7.1 Bypassing Agents - Take appropriate precautions when treating break-through bleeding events in hemophilia patients receiving Alhemo prophylaxis and a bypassing agent [see Dosage and ...
  • 8 USE IN SPECIFIC POPULATIONS
    8.1 Pregnancy - Risk Summary - Based on its mechanism of action, Alhemo may cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data ...
  • 11 DESCRIPTION
    Concizumab-mtci, is a humanized IgG4 monoclonal antibody produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cells with an approximate molecular weight of 149 kDa. Alhemo ...
  • 12 CLINICAL PHARMACOLOGY
    12.1 Mechanism of Action - Concizumab-mtci is a monoclonal antibody antagonist of endogenous Tissue Factor Pathway Inhibitor (TFPI). Through the inhibition of TFPI, concizumab-mtci acts to ...
  • 13 NONCLINICAL TOXICOLOGY
    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility - No long-term animal studies have been conducted to evaluate the carcinogenic potential of concizumab-mtci nor have studies been ...
  • 14 CLINICAL STUDIES
    Hemophilia A and B with Inhibitors in Patients ≥12 Years of Age (explorer7) The efficacy of Alhemo in patients with hemophilia A and B with inhibitors was evaluated in the explorer7 trial ...
  • 16 HOW SUPPLIED/STORAGE AND HANDLING
    How Supplied - Alhemo (concizumab-mtci) injection is a clear to slightly opalescent, colorless to slightly yellow liquid, that may contain translucent to white particles. Alhemo is available as ...
  • 17 PATIENT COUNSELING INFORMATION
    Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use). • Thromboembolic events: Inform patients of the signs and symptoms of thromboembolic ...
  • Medication Guide
    MEDICATION GUIDE - Alhemo® (al-HEE-mo) (concizumab-mtci) injection, for subcutaneous use - What is the most important information I should know about Alhemo? • It is important to ...
  • Instructions for Use – 1.5 mL (60 mg)
    INSTRUCTIONS FOR USE - Alhemo® (al-HEE-mo) (concizumab-mtci) injection, for subcutaneous use - 60 mg/1.5 mL (40 mg/mL) single-patient-use prefilled pen - This Instructions for Use contains ...
  • Instructions for Use – 1.5 mL (100 mg)
    INSTRUCTIONS FOR USE - Alhemo® (al-HEE-mo) (concizumab-mtci) injection, for subcutaneous use - 150 mg/1.5 mL (100 mg/mL) single-patient-use prefilled pen - This Instructions for Use ...
  • Instructions for Use – 3.0 mL (300 mg)
    INSTRUCTIONS FOR USE - Alhemo® (al-HEE-mo) (concizumab-mtci) injection, for subcutaneous use - 300 mg/3 mL (100 mg/mL) single-patient-use prefilled pen - This Instructions for Use contains ...
  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 60 mg
    NDC 0169-2084-15 List: 208415 -   Alhemo®   (concizumab-mtci) injection 60 mg/1.5 mL (40 mg/mL) For subcutaneous use only - 1x1.5 mL single-patient use prefilled pen - Dials in ...
  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 150 mg
    NDC 0169-2080-15 List: 208015 -   Alhemo®   (concizumab-mtci) injection - 150 mg/1.5 mL (100 mg/mL) For subcutaneous use only - 1x1.5 mL single-patient use prefilled pen - Dials in 1 mg ...
  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 300 mg
    NDC 0169-2081-03 List : 208103 -   Alhemo®   (concizumab-mtci) injection - 300 mg/3 mL (100 mg/mL) Prefilled Pen - For subcutaneous use only - 1x3 mL single-patient use prefilled ...
  • INGREDIENTS AND APPEARANCE
    Product Information